The American Journal of Managed Care4h
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...
Monthly Prescribing Reference6h
New Tablet Formulation of SMA Therapy Evrysdi Gets FDA Approval
The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.
FiercePharma7h
Roche nabs FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
F. Hoffmann-La Roche Ltd: FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and sa ...
Roche announces FDA approves Evrysdi tablet to treat SMA
Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...
MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
FDA approves new genetic disorder drug
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...
Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues
Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...
Cure Today2d
Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
Stocktwits on MSN2d
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Business Wire2d
LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...
ophthalmologyadvisor2d
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...